| Carl J Viviano, MD | |
|
3300 Westhill Dr, Wausau, WI 54401-4710 | |
| (715) 847-2605 | |
| (715) 847-2604 |
| Full Name | Carl J Viviano |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 33 Years |
| Location | 3300 Westhill Dr, Wausau, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811925829 | NPI | - | NPPES |
| 31685400 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 31967-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspirus Wausau Hospital | Wausau, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Medical Group Inc | 1052223625 | 212 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
| Entity Name | Aspirus Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669595294 PECOS PAC ID: 1052223625 Enrollment ID: O20031103000267 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
| Entity Name | Aspirus Wausau Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922321140 PECOS PAC ID: 6406757442 Enrollment ID: O20040114000297 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
| Entity Name | Langlade Hospital - Hotel Dieu Of St Joseph Of Antigo Wisconsin |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831251040 PECOS PAC ID: 1557271202 Enrollment ID: O20040212000310 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
| Entity Name | Urology Specialists Of Wisconsin S.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831132018 PECOS PAC ID: 2365428950 Enrollment ID: O20040625000044 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carl J Viviano, MD 3300 Westhill Dr, Wausau, WI 54401-4710 Ph: (715) 847-2605 | Carl J Viviano, MD 3300 Westhill Dr, Wausau, WI 54401-4710 Ph: (715) 847-2605 |
News Archive
Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.
Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
After passing universal coverage, Massachusetts is now in the throes of a debate about how to bring down its skyrocketing health care costs. And the state's new proposal to regulate how much providers charge for health care could mark a very important and controversial chapter in that fight.
Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.
› Verified 3 days ago
Kenneth Lowell Day, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 2603 Teal Ave (residence), Wausau, WI 54401 Phone: 715-842-7019 | |
Laura E Sherrill, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3300 Westhill Dr, Wausau, WI 54401 Phone: 715-847-2605 Fax: 715-847-2604 | |
Benjamin S Battino, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3300 Westhill Dr, Wausau, WI 54401 Phone: 715-847-2605 Fax: 715-847-2604 | |
Roy A Brandell, M.D. Urology Medicare: Medicare Enrolled Practice Location: 3300 Westhill Dr, Wausau, WI 54401 Phone: 715-847-2605 Fax: 715-847-2604 | |
Joseph W Babiarz, M.D. Urology Medicare: Medicare Enrolled Practice Location: 3300 Westhill Dr, Wausau, WI 54401 Phone: 715-847-2605 Fax: 715-847-2604 |